Phase 3 N=51 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=634 A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Mean Change In Hemoglobin From TP Baseline To TP Week 5 Following The First Course Of Ferumoxytol — 2.6 g/dL — p=<0.0001
Phase 3 N=1,011 Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
Iron Deficiency Anemia
Primary: Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for…
Phase 3 N=812 A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Participants Who Achieved A ≥2.0 g/dL Increase In Hemoglobin At Any Time From Baseline To Week 5 — 252; 5; 386; 7 Participants — p=<0.0001
Phase 4 N=88 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Ulcerative Colitis · Crohn's Disease
Primary: Mean Change in Haemoglobin Concentration. — 1.22; 1.30 g/dl — p=0.23
N/A N=809 Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?
Anemia · Iron Deficiency · Hemoglobin Disorder
Primary: Hemoglobin Levels at 12-weeks. Marginal Means (95% CI). — 123; 116; 121; 116 g/L — p=<0.05
Phase 3 N=1 Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)
Iron Deficiency Anemia · Iron-deficiency
Primary: Percentage of Eligible Patients Enrolled — 1; 0 Participants
Phase 3 N=626 Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Iron Deficiency Anaemia · Chronic Kidney Disease
Primary: Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger — 36; 49; 98; 117 participants — p=0.026
Phase 3 N=1,512 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 2.49; 2.49 g/dL
Phase 3 N=167 Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
Renal Insufficiency, Chronic · Iron-Deficiency Anemia
Primary: Change in Hb Concentration From Baseline to Week 16 — 0.50; -0.02 g/dl — p=0.0149
Phase 4 N=38 Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
Iron Deficiency Anemia of Pregnancy · Iron Malabsorption
Primary: Maternal Anemia at Delivery — 4; 11 Participants — p=0.039
Phase 2 N=93 Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)
Restless Legs Syndrome · Iron Deficiency Anemia
Primary: Change From Baseline in the Restless Legs Syndrome Rating Scale — -14.0000; -9.7353 units on a scale — p=0.2742
Phase 3 N=2,014 A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
Iron Deficiency Anemia
Primary: Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension — 3; 6; 1; 0…
Phase 3 N=250 Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
Anemia, Iron-Deficiency · Inflammatory Bowel Disease · Crohn's Disease
Primary: Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12 — 84; 105; 41; 20 Participants — p=0.298
Phase 2 N=49 Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
Iron Deficiency Anemia
Primary: Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane) — -11.90; -1.06; -12.37; -11.14 mg
Phase 3 N=351 Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia
Iron Deficiency Anemia · Chronic Kidney Disease
Primary: Change in Hemoglobin (Hb) Concentration From Baseline to Week 4. — 0.57; 0.35 g/dL
Phase 3 N=122 Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) — 5; 42 Participants — p=<0.0001
Phase 4 N=198 Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
Primary: Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders). — 60; 34 Participants
Phase 3 N=1,538 Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
Iron Deficiency Anaemia · Iron Deficiency Anemia · Chronic Kidney Disease
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 1.22; 1.14 g/dL
Phase 3 N=123 Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
Iron Deficiency Anaemia · Iron Deficiency Anemia
Primary: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) — 5; 45 Participants — p=<0.0001
Phase 3 N=511 IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
Iron Deficiency Anaemia
Primary: Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5 — 226; 83 participants
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
Phase 2 N=35 A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA
Iron Deficiency Anemia (IDA)
Primary: Maximum Serum Concentration (Cmax) — 157; 310 µg/mL
Phase 3 N=2,584 Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
Iron Deficiency Anemia · Impaired Renal Function
Primary: Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study. — 1.13; 0.92 g/dL
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
Phase 2 N=56 IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients
Pulmonary Arterial Hypertension · Iron Deficiency
Primary: Change in Exercise Capacity - Endurance — 315.44; 302.89 Seconds — p=0.6039
Phase 3 N=605 A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Participants Who Achieved A ≥2.0 g/dL Increase In Hemoglobin At Any Time From Baseline To Week 5 — 291; 117; 327; 145 Participants — p=0.2833
Phase 1 N=37 Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
Iron Deficiency, Anaemia in Children · Iron-Deficiency
Primary: Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1 — 2.4518; 1.1632; 0.5299 mg/L
Phase 3 N=40 Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure
Anemia · Renal Failure
Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L